Non-Invasive Intracranial Pressure Monitoring Devices Market Size and Share

Non-Invasive Intracranial Pressure Monitoring Devices Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Non-Invasive Intracranial Pressure Monitoring Devices Market Analysis by Mordor Intelligence

The non-invasive intracranial pressure monitoring devices market size was valued at USD 372.57 million in 2025 and estimated to grow from USD 389.78 million in 2026 to reach USD 488.69 million by 2031, at a CAGR of 4.62% during the forecast period (2026-2031). Incremental expansion reflects the shift from exploratory prototypes to clinically validated solutions that match invasive accuracy while avoiding surgical risks, lowering infection rates and shortening hospital stays. Military research grants, FDA breakthrough-device designations and expanding evidence for AI-enabled waveform analytics are accelerating clinical adoption. Hospitals remain the chief customers, yet rapid uptake in emergency departments, ambulatory centers and home-care programs signals a move toward decentralized monitoring. Asia-Pacific’s demographic pressure and infrastructure build-out underpin the fastest regional CAGR, whereas North America leverages reimbursement frameworks and defense spending to protect its leadership position.

Key Report Takeaways

  • By device type, transcranial Doppler ultrasonography led with 37.05% of the non-invasive intracranial pressure monitoring devices market share in 2025; infrared pupillometry is projected to advance at an 11.05% CAGR through 2031.
  • By application, traumatic brain injury accounted for a 39.93% slice of the non-invasive intracranial pressure monitoring devices market size in 2025; stroke monitoring is expanding at a 9.37% CAGR to 2031.
  • By end user, hospitals held 55.72% revenue share in 2025, while home healthcare is set to post a 9.12% CAGR between 2026-2031.
  • By geography, North America controlled 37.90% of the non-invasive intracranial pressure monitoring devices market size in 2025; Asia-Pacific is the fastest-growing region with an 8.11% CAGR forecast to 2031.

Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.

Non-Invasive Intracranial Pressure Monitoring Devices Market Segment Analysis

By Device Type:

Transcranial Doppler Leads Despite Infrared Innovation

Transcranial Doppler held a 37.05% non-invasive intracranial pressure monitoring devices market share in 2025 owing to its established role in vasospasm detection, stroke risk screening and bedside cerebral hemodynamics assessment. Automated waveform storage, portable form factors and protocol standardization have kept adoption robust. The segment benefits from extensive reimbursement coverage and clinician familiarity, anchoring the non-invasive intracranial pressure monitoring devices market size on a solid installed base. 

Infrared pupillometry is set for an 11.05% CAGR through 2031 as short-wave infrared cameras deliver touchless readings through closed eyelids, expanding monitoring to sedated or intubated patients. Devices that calculate the Neurological Pupil Index provide objective early warnings of intracranial hypertension, reducing reliance on subjective light-reflex checks. Tympanic membrane displacement and optic-nerve diameter tools serve niche applications where specific anatomic windows or pediatric use dictate alternate approaches. MRI/CT-based estimates remain constrained by cost, radiation exposure and limited repeatability, but may support complex cases requiring multimodal confirmation. Continuous improvements in algorithmic fusion of Doppler and pupillometry promise hybrid platforms that elevate diagnostic confidence while trimming operator training demands.

Non-Invasive Intracranial Pressure Monitoring Devices Market: Market Share by Device Type, 2025
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Non-Invasive Intracranial Pressure Monitoring Devices Market: Market Share by Device Type, 2025

By Application:

Traumatic Brain Injury Dominance Challenged by Stroke Acceleration

Traumatic brain injury represented 39.93% of the non-invasive intracranial pressure monitoring devices market in 2025, driven by defense-sector funding, sports-medicine protocols and motor-vehicle trauma prevalence. Surgeons rely on continuous pressure readings to forestall secondary injury from uncontrolled edema. Military mandates for baseline cognitive testing ensure early deployment of monitoring technology throughout active duty and veteran care pathways. 

Stroke monitoring is advancing at a 9.37% CAGR as guidelines now recommend continuous intracranial pressure tracking to guide hyperosmolar therapy and blood-pressure titration in both ischemic and hemorrhagic events. Early-warning algorithms detect subtle pressure elevations that herald neurologic decline, enabling faster intervention. Intracerebral hemorrhage, meningitis and hydrocephalus collectively comprise a meaningful share, each benefitting from non-invasive options that circumvent infection risks in fragile patients. New clinical trials exploring multimodal bundles—combining intracranial pressure, cerebral perfusion and oxygenation—signal further expansion opportunities over the forecast.

By End User:

Hospital Dominance Faces Home Healthcare Disruption

Hospitals controlled 55.72% of the non-invasive intracranial pressure monitoring devices market size in 2025 as neuro-ICUs standardize advanced monitoring for complex cases. Integration into electronic records and established purchasing frameworks protect incumbent sales channels. Academic centers also conduct validation studies, reinforcing hospital influence on purchasing standards and clinical protocols. 

Home healthcare is forecast to register a 9.12% CAGR through 2031 due to FDA guidance that now facilitates remote neuro-monitoring platforms. Elderly and chronic-care patients benefit from wearable sensors that transmit secure data to central dashboards, curbing readmissions and enhancing quality of life. Neurology clinics and ambulatory centers occupy a middle ground, leveraging non-invasive solutions for same-day procedures and outpatient follow-up. As payors bolster reimbursement for remote physiologic monitoring, home-based deployments will chip away at hospital dominance, reshaping long-term revenue distribution within the non-invasive intracranial pressure monitoring devices market.

Non-Invasive Intracranial Pressure Monitoring Devices Market: Market Share by End User, 2025
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Non-Invasive Intracranial Pressure Monitoring Devices Market: Market Share by End User, 2025

Geography Analysis

North America Non-Invasive Intracranial Pressure Monitoring Devices Market

North America accounted for 37.90% of the non-invasive intracranial pressure monitoring devices market in 2025 amid sizable research budgets, robust reimbursement and the Department of Defense’s USD 3.2 million grant to refine blast-TBI screening. FDA breakthrough-device pathways shorten time-to-market for innovators, while Level 1 trauma centers set clinical standards that ripple across community hospitals. Canada’s single-payer environment supports steady device procurement, and Mexico’s public-health expansions are adding advanced neuromonitoring units in select tertiary hubs.

APAC Non-Invasive Intracranial Pressure Monitoring Devices Market

Asia-Pacific is the fastest-growing region with an 8.11% CAGR to 2031, supported by rising traumatic injury rates, aging demographics and expanding critical-care capacity. China’s revision of the National Medical Products Administration (NMPA) approval process is creating clearer on-ramps for imported and locally produced monitors. Japan and South Korea drive early adoption of AI-enhanced platforms, while India demonstrates high receptivity to cost-effective handheld Doppler solutions capable of operating in resource-sparse districts. Government health-tech incentives and local manufacturing tie-ups are expected to amplify installed bases.

Europe Non-Invasive Intracranial Pressure Monitoring Devices Market

Europe maintains a steady position, anchored by rigorous evidence-based guidelines and cross-border collaboration on multicenter trials exploring multimodal neuromonitoring. Germany, the United Kingdom and France lead acquisitions, whereas Southern and Eastern European systems embrace shared-service networks to pool capital expenditure. Medical Device Regulation (MDR) compliance has lengthened certification timelines yet boosts clinician confidence once devices clear review. Constrained budgets remain a headwind, but pan-EU research grants and vendor financing schemes help sustain device turnover.

Non-Invasive Intracranial Pressure Monitoring Devices Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The non-invasive intracranial pressure monitoring devices market shows moderate concentration, with the top five manufacturers estimated to hold a significant share in 2025. Integra LifeSciences promotes its CereLink system while rectifying manufacturing observations cited in an FDA warning letter in December 2024. Nihon Kohden’s November 2024 purchase of a controlling stake in NeuroAdvanced expands its EEG and intracranial electrode offerings, underscoring a push toward multimodal neurological platforms.

Start-ups focus on AI algorithms that retrofit to existing bedside monitors, reducing capital hurdles for hospitals and accelerating revenue capture. Military R&D programs continue to seed early-stage ventures targeting blast-related trauma, which often migrate into civilian trauma-unit use. Device makers are also forging distribution alliances in Asia-Pacific to navigate local regulatory pathways and cut time-to-launch. 

Strategically, vendors differentiate through software capabilities, cloud-integrated dashboards and training packages that counter the neuro-sonographer shortage. Subscription-based analytics models shift revenue from one-off hardware sales to recurring fees, smoothing cash flow and encouraging continual software upgrades. Litigation risk remains moderate because devices do not pierce the dura, but quality-system rigor is increasingly scrutinized: manufacturing lapses can result in stern FDA action, as evidenced in 2024. Long-term, players able to bundle intracranial pressure, EEG and cerebral oximetry within a single interface should command premium pricing.

Non-Invasive Intracranial Pressure Monitoring Devices Industry Leaders

  1. RAUMEDIC AG

  2. Nisonic

  3. Natus Medical

  4. Integra LifeSciences

  5. Medtronic plc

  6. *Disclaimer: Major Players sorted in no particular order
Non-Invasive Intracranial Pressure Monitoring Devices Market  Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Non-Invasive Intracranial Pressure Monitoring Devices Market Companies Covered in this Report

  • Integra LifeSciences
  • Medtronic
  • RAUMEDIC
  • Sophysa
  • Spiegelberg
  • Natus Medical
  • Viasonix
  • NovaSignal
  • Nisonic
  • RIMED
  • Compumedics
  • Dragerwerk
  • Koninklijke Philips
  • Nihon Kohden
  • GE Healthcare
  • Brain4Care
  • HeadSense Medical
  • Luciole Medical
  • IRRAS AB
  • De Cranio Solutions

Read Analysis of Non-Invasive Intracranial Pressure Monitoring Devices Companies

Market Opportunities and Future Outlook

White-space in non-invasive intracranial pressure (ICP) monitoring centers on reducing operator dependency while improving comparability to invasive reference measurements, especially in emergency and decentralized settings. Brain4Care’s FDA 510(k) clearance in March 2024 (K240821) for the B4C System (Class II intracranial pressure monitoring device) supports broader procurement beyond investigational use. The pipeline is also reflected in early feasibility work such as CoMind Technologies Limiteds CoMind One EFS (ClinicalTrials.gov NCT06368648, initiated November 2024), which focuses on model-driven, non-invasive estimation approaches, with robust head-to-head clinical validation remaining a gating item for wider protocol inclusion.

Technology roadmaps are shifting toward multimodal data fusion and AI-enabled waveform analytics that leverage routinely captured ICU signals (ECG, arterial blood pressure, photoplethysmography), rather than specialized, operator-intensive procedures. Recent 2026 publications describing passive waveform sensing and deep-learning reconstruction of ICP waveforms from standard bedside inputs reinforce the case for software-forward offerings that integrate with existing monitors and clinical dashboards, which can help address acquisition-cost and workforce constraints (including neuro-sonographer scarcity). The development split between passive wearable-style non-invasive sensors and higher-accuracy, longer-term monitoring approaches (including implantable remote monitoring research programs) also suggests differentiated use cases across traumatic brain injury, stroke monitoring, and chronic hydrocephalus follow-up. This aligns with the shift from hospital-only use toward ED, ambulatory, and home-care pathways already reflected in end-user adoption patterns.

Recent Industry Developments in Non-Invasive Intracranial Pressure Monitoring Devices Market

  • June 2026: Academic researchers reported a deep learning framework to reconstruct intracranial pressure waveforms from routinely acquired ICU signals (such as ECG, arterial blood pressure, and photoplethysmography). The work supports a software-centric path to extend non-invasive ICP estimation without adding dedicated bedside hardware. It also aligns with hospital demands for scalable monitoring across more beds amid neuro-sonographer shortages.
  • August 2025: Medtronic plc launched the NEUROVENT PTO intracranial pressure monitoring catheter for real-time ICP tracking. Although invasive, the launch highlights continued investment in ICP monitoring performance and workflow integration that shapes the clinical benchmarks used to validate non-invasive alternatives.
  • March 2024: Brain4Care received FDA 510(k) clearance (K240821) for the B4C System, including the BcSs-PICNIW-2000 sensor model, as a Class II intracranial pressure monitoring device. Clearance improves procurement confidence and supports broader clinical deployment beyond investigational settings.

Table of Contents for Non-Invasive Intracranial Pressure Monitoring Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences Of Neurological Disorders
    • 4.2.2 Rising Preference For Minimally- & Non-Invasive Procedures
    • 4.2.3 Wider Adoption Of Point-Of-Care Ultrasound In ED/ICU
    • 4.2.4 Growing Use Of Multimodal Neuromonitoring Bundles
    • 4.2.5 AI-Enabled Waveform Analytics Improving Diagnostic Accuracy
    • 4.2.6 Military R&D Funding For Blast-TBI Screening Devices
  • 4.3 Market Restraints
    • 4.3.1 Lack Of Trained Neuro-Sonographers
    • 4.3.2 High Device Acquisition & Maintenance Costs
    • 4.3.3 Variability In Non-Invasive Algorithm Accuracy
    • 4.3.4 Slow Reimbursement Code Expansion For Emergent Settings
  • 4.4 Technological Outlook
  • 4.5 Porter's Five Forces
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Device Type
    • 5.1.1 Transcranial Doppler Ultrasonography
    • 5.1.2 Tympanic Membrane Displacement
    • 5.1.3 Optic Nerve Sheath Diameter
    • 5.1.4 MRI / CT-based Estimation
    • 5.1.5 Infrared Pupillometry
    • 5.1.6 Others
  • 5.2 By Application
    • 5.2.1 Traumatic Brain Injury
    • 5.2.2 Intracerebral Hemorrhage
    • 5.2.3 Meningitis
    • 5.2.4 Hydrocephalus
    • 5.2.5 Stroke
    • 5.2.6 Others
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Neurology Clinics
    • 5.3.3 Ambulatory Surgical Centers
    • 5.3.4 Home-care Settings
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Integra LifeSciences
    • 6.3.2 Medtronic plc
    • 6.3.3 RAUMEDIC
    • 6.3.4 Sophysa
    • 6.3.5 Spiegelberg
    • 6.3.6 Natus Medical
    • 6.3.7 Viasonix
    • 6.3.8 NovaSignal
    • 6.3.9 Nisonic
    • 6.3.10 RIMED
    • 6.3.11 Compumedics
    • 6.3.12 Dragerwerk
    • 6.3.13 Philips Healthcare
    • 6.3.14 Nihon Kohden
    • 6.3.15 GE Healthcare
    • 6.3.16 Brain4Care
    • 6.3.17 HeadSense Medical
    • 6.3.18 Luciole Medical
    • 6.3.19 IRRAS AB
    • 6.3.20 De Cranio Solutions

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment

Non-Invasive Intracranial Pressure Monitoring Devices Market Report Scope and Research Methodology

Market Definition and Coverage

This market covers devices that measure or estimate intracranial pressure without an invasive catheter, and the value reflects device-level revenues captured across clinical care settings where ICP assessment is used.

Scope exclusions: We exclude invasive ICP monitors and procedure related hospital service revenues that sit outside device sales.

Segments Covered in This Report

  • By Device Type
    • Transcranial Doppler Ultrasonography
    • Tympanic Membrane Displacement
    • Optic Nerve Sheath Diameter
    • MRI / CT-based Estimation
    • Infrared Pupillometry
    • Others
  • By Application
    • Traumatic Brain Injury
    • Intracerebral Hemorrhage
    • Meningitis
    • Hydrocephalus
    • Stroke
    • Others
  • By End User
    • Hospitals
    • Neurology Clinics
    • Ambulatory Surgical Centers
    • Home-care Settings
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Data Sources, Market Sizing, and Validation

Desk Research

Desk research started with clarifying clinical use and device pathways so the demand pool stays tied to neurocritical care and neurology workflows. We reviewed public sources such as FDA device databases (510(k) and De Novo summaries), clinical guidance from bodies such as the Brain Trauma Foundation, and peer reviewed journals that discuss non-invasive ICP proxies and accuracy metrics.

To keep the model grounded, we also pulled supporting signals from sources such as the World Health Organization (injury burden), CDC datasets (head injury and emergency care context), and OECD health statistics (health system capacity indicators). Company annual reports, investor decks, and reputable press coverage were used to understand product launches and geographic commercialization, and paid subscriptions were used selectively for company financials and patent landscaping where disclosures were thin. The sources listed here are illustrative, and many other public documents and datasets were reviewed for data collection, cross-checks, and clarification.

Primary Interviews and Surveys

Primary work focused on pressure-monitoring decision points in hospitals and critical care, and how non-invasive tools are chosen versus invasive monitoring for different patient groups. We spoke with device side leaders, clinical users, and channel participants across major regions so pricing logic, adoption barriers, and replacement cycles could be confirmed when desk sources did not provide clean answers.

Distribution of primary research fieldwork respondents

Company typeRespondent positionRegion
Top tier: 31% CXOs: 17%APAC: 39%
Mid tier: 52% Functional/Unit leaders: 40%EMEA: 34%
Smaller Players: 17% Managers: 43%Americas: 27%

Market-Sizing & Forecasting

Sizing is built by reconstructing the demand pool from clinical activity and care capacity, and then converting it into device revenues using realistic adoption and price assumptions. The top-down approach is anchored on indicators such as neuro ICU and emergency care throughput, traumatic brain injury and intracranial hemorrhage caseload direction, ICU bed availability, and the practical share of cases where non-invasive ICP assessment is used as a screening or monitoring step.

Those demand signals are translated into revenues using a small set of working inputs, such as device utilization per facility, replacement cycles, average selling price ranges by device class, and expected shifts in adoption as evidence quality improves. To keep the totals grounded, we corroborated the outputs with selective bottom-up approximations, including sampled supplier revenue disclosures, channel checks on installed base, and ASP validation from procurement style conversations. Any missing pieces were handled through conservative ranges that were tightened during expert follow-ups.

For forecasting, scenario analysis was used so changes in clinical acceptance, reimbursement direction, and hospital capital budgets can be reflected without overfitting. Assumptions for adoption lift and ASP progression were adjusted only after the primary inputs aligned with what clinicians and commercial teams see in routine purchasing cycles.

Data Validation & Update Cycle

Validation is done through stepwise checks so the final number matches independent signals and stays explainable. We review outputs against clinical volume indicators, regional health spending direction, and observable product activity, and then we flag outliers that come from unrealistic penetration, price jumps, or sudden mix changes.

Before sign-off, a second analyst reviews the model build and key assumptions, followed by targeted re-contact when a large variance cannot be explained by a clear market event. Reports are refreshed annually, and interim updates are triggered when material events occur (for example, major regulatory clearances or meaningful pricing shifts). Before delivery, a fresh review pass is completed so clients receive the most current version available.

Mordor Intelligence's Non Invasive Intracranial Pressure Monitoring Devices Market Size Compared Against Other Published Estimates

It is normal to see different published market sizes for this topic because the scope line is easy to move and the evidence base is still evolving. Differences usually come from what gets counted as non-invasive ICP monitoring, how pricing is treated across care settings, and how quickly assumptions are refreshed after new clinical results or regulatory milestones.

Some estimates broaden the market by folding in invasive ICP monitoring systems or adjacent neuromonitoring tools that do not directly estimate intracranial pressure. In the Mordor Intelligence view, revenue is counted only for non-invasive ICP monitoring devices, and related neuromonitoring categories are excluded even if they are used in the same ICU workflow.

Benchmark comparison

SourceMarket SizeGaps in Research Methodology
Mordor Intelligence USD 389.78 M (2026)
Global Consultancy A USD 482.60 M (2026)Uses a wider device basket and applies faster adoption and price uplift assumptions, which can pull in adjacent neuromonitoring instruments and inflate the addressable revenue pool.
Industry Publisher B USD 96.00 M (2024)Tracks a narrower set of manufacturers and often emphasizes shipped volumes and average prices for a limited product subset, which can understate broader clinical usage across regions and settings.

The spread across figures is mostly explained by category inclusions and how quickly penetration is allowed to rise in forecasts. By keeping the counted revenues tied to non-invasive ICP monitoring device sales and cross-checking with clinical activity signals and real-world pricing feedback, the estimate remains traceable to clear inputs and repeatable steps.

Key Questions Answered in the Report

How large is the non-invasive intracranial pressure monitoring devices market in 2026?

The market stands at USD 389.78 million and is projected to reach USD 488.69 million by 2031, implying a 4.62% CAGR.

Which device type currently dominates sales?

Transcranial Doppler ultrasonography leads with a 37.05% share thanks to broad clinical validation and reimbursement support.

What is the fastest-growing application segment?

Continuous stroke monitoring shows the highest forecast growth at a 9.37% CAGR through 2031.

Which region offers the highest growth potential?

Asia-Pacific is set to expand at an 8.11% CAGR due to demographic shifts and expanding critical-care capacity.

How is artificial intelligence influencing adoption?

AI-enabled waveform analytics deliver invasive-level accuracy via standard monitors, reducing operator dependency and widening clinical uptake.

What restrains faster market penetration?

A global shortage of trained neuro-sonographers and high upfront equipment costs remain primary barriers despite rising demand.

Page last updated on: